摘要
目的探讨替格瑞洛在中国急性冠脉综合征(acute coronary syndrome,ACS)患者中的1年期疗效及总结治疗经验。方法选择2012年9月至2013年7月入南京军区福州总医院心内科,诊断为ACS的患者199例,其中服用替格瑞洛患者96例,服用氯吡格雷患者103例。替格瑞洛组给予180 mg负荷剂量口服,后90 mg每日两次维持。氯吡格雷组给予300/600 mg口服,后服用氯吡格雷维持剂量75 mg/d。所有患者均给予阿司匹林。比较两组的基础临床资料,观察两组服药1个月、半年、1年的不良事件,并对两组1年的主要心血管事件和出血情况进行比较。结果两组间基础临床资料比较,差异无统计学意义(P>0.05)。替格瑞洛组心血管死亡(2.1%vs.2.9%)、心肌梗死(1.0%vs.1.9%)、卒中(1.0%vs.1.9%)、支架内血栓(1.0%vs.1.9%)、再发心绞痛(5.2%vs.5.8%)少于氯吡格雷组;呼吸困难(5.2%vs.1.9%)、心动过缓(3.1%vs.1.9%)、主要出血(4.2%vs.2.9%)和次要出血(3.1%vs.2.9%)多于氯吡格雷组,但均差异无统计学意义(P>0.05)。替格瑞洛组主要心血管事件总和低于氯吡格雷组(5.2%vs.8.7%),主要出血和次要出血总和高于氯吡格雷组(7.2%vs.5.8%),但差异无统计学意义(P>0.05)。结论替格瑞洛在中国患者中的1年期临床疗效确切,具有良好的安全性和耐受性。
Objective To discuss the efficacy and safety of ticagrelor in Chinese patients with acute coronary syndrome（ACS）. Methods A total of 199 patients with ACS in Fuzhou General Hospital of Nanjing Command from September2012 to July 2013 were enrolled. Ninety-six of them were given ticagrelor（oral loading dose of 180 mg ＋ maintenance dose of 90 mg twice per day） and the other 103 were given clopidogrel（oral dose of 300 / 600 mg＋ maintenance dose of 75 mg per day）. All the patients received aspirin. We observed the adverse events in 1 month, 6 months and 1 year,and compared the baseline data, incidences of cardiovascular events and bleeding events in one year between the two groups. Results There was no significant difference in basic clinical data and related routine examination results between the two groups（P〉0.05）. Patients receiving ticagrelor had lower occurrence rates in cardiovascular death（2.1% vs. 2.9%）, myocardial infarction（1.0% vs. 1.9%）, stroke（1.0% vs. 1.9%）, stent thrombosis（1.0% vs.1.9%） and recurrent angina pectoris（5.2% vs. 5.8%） and higher occurrence rates in dyspnea（5.2% vs. 1.9%）,bradycardia（3.1% vs. 1.9%）, major bleeding（4.2% vs. 2.9%） and minor bleeding（3.1% vs. 2.9%） than those receiving clopidogrel with no significant difference（P〉0.05）. The occurrence rate of major adverse cardiovascular events was lower in patients receiving ticagrelor than in those receiving clopidogrel with no significant difference（5.2%vs.8.7%,P〉0.05）. The total occurrence rate of major bleeding and minor bleeding was higher in those receiving ticagrelor than in those receiving clopidogrel with no significant difference（7.2% vs.5.8%;P〉0.05）. Conclusions The efficacy and safety of ticagrelor in Chinese patients with ACS are creditable.
出处
《岭南心血管病杂志》
2015年第3期285-289,共5页
South China Journal of Cardiovascular Diseases
基金
福建省自然科学基金(项目编号:2013J01343)
南京军区科技人才培养工程重点资助科研项目(项目编号:12RC04)
南京军区福州总医院2012年科研基金资助项目(项目编号:Y201203)
关键词
冠状动脉疾病
替格瑞洛
心血管事件
早期疗效
安全性
coronary artery disease
ticagrelor
adverse cardiovascular events
efficacy
safety
